SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-031494
Filing Date
2024-03-14
Accepted
2024-03-14 16:15:37
Documents
96
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K kzr-20231231.htm   iXBRL 10-K 2643565
2 EX-4.2 kzr-ex4_2.htm EX-4.2 32475
3 EX-10.11 kzr-ex10_11.htm EX-10.11 19376
4 EX-23.1 kzr-ex23_1.htm EX-23.1 2484
5 EX-31.1 kzr-ex31_1.htm EX-31.1 14492
6 EX-31.2 kzr-ex31_2.htm EX-31.2 14334
7 EX-32.1 kzr-ex32_1.htm EX-32.1 9591
8 EX-97.1 kzr-ex97_1.htm EX-97.1 54638
9 GRAPHIC img39262056_0.jpg GRAPHIC 765457
  Complete submission text file 0000950170-24-031494.txt   12764651

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20231231.xsd EX-101.SCH 1545820
98 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20231231_htm.xml XML 2035630
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38542 | Film No.: 24750337
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)